Krebs Biochemicals and Industries Limited (KREBSBIO) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Krebs Biochemicals and Industries Limited stock ₹50.67, price ₹58.79, that is 13.8% below the price, quality 25 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Krebs Biochemicals and Industries Limited
KREBSBIO · NSEExpensive (fair value 14% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.
How to read this chart
60‑month range ₹39.75 – ₹213.05 · fair‑value band ₹38.00 – ₹63.34 · the ₹58.79 price screens above the ₹50.67 fair value. As of Nov 13, 2026.
Every Wednesday you see whether Krebs Biochemicals and Industries is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry.
Show moreShow less
Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications.
The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications.
In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India.
Stock analysis
Krebs Biochemicals and Industries Limited (KREBSBIO) currently trades at ₹58.79, while our estimate is ₹50.67, 14% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: ₹38.00 (bear) to ₹63.34 (bull), the price of ₹58.79 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Krebs Biochemicals and Industries Limited reported revenue of ₹237M in FY2026 versus ₹597M in FY2022, a compound −20.6%/yr. Reported net income was −₹169M in FY2026.
Key figures
Market cap ₹1.3B (≈ $13.5M) Micro · P/S ratio 4.95 · EPS (TTM) ₹−6.54 · Net margin −55.9% · Return on assets (EBIT) −12.4% (5-year average) · Operating margin −8.7% · Revenue (TTM) ₹252M · Revenue growth (YoY) +27.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 18% below its 52-week high and 48% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −14%, KREBSBIO screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
KREBSBIO screens overvalued: fair value 14% below the price. Compare with Merck KGaA →
Compare Krebs Biochemicals and Industries Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs KREBSBIO |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs KREBSBIO |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs KREBSBIO |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs KREBSBIO |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs KREBSBIO |
| Galderma Group GALD | CHF 191.00 | CHF 112.30 | −41% | vs KREBSBIO |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs KREBSBIO |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs KREBSBIO |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs KREBSBIO |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs KREBSBIO |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Krebs Biochemicals and Industries Limited (KREBSBIO) overvalued or undervalued?
What is the fair value of KREBSBIO?
What is the quality score of KREBSBIO?
What is the price target for Krebs Biochemicals and Industries Limited (KREBSBIO)?
What is the Krebs Biochemicals and Industries Limited stock forecast for 2026?
What is the revenue of Krebs Biochemicals and Industries Limited (KREBSBIO)?
What is the intrinsic value of Krebs Biochemicals and Industries Limited (KREBSBIO)?
Is Krebs Biochemicals and Industries Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of KREBSBIO?
How much is Krebs Biochemicals and Industries Limited worth?
What do the bullish and bearish scenarios say about KREBSBIO?
How solid is the balance sheet of Krebs Biochemicals and Industries Limited (KREBSBIO)?
How far is KREBSBIO from its 52-week high?
Which stocks are comparable to Krebs Biochemicals and Industries Limited?
Is Krebs Biochemicals and Industries Limited stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Krebs Biochemicals and Industries Limited (KREBSBIO)?
What should I pay attention to with Krebs Biochemicals and Industries Limited right now?
Key figures of Krebs Biochemicals and Industries Limited
How large is the market capitalisation of Krebs Biochemicals and Industries Limited (KREBSBIO)?
What is the P/S ratio of Krebs Biochemicals and Industries Limited (KREBSBIO)?
What are the earnings per share of Krebs Biochemicals and Industries Limited (KREBSBIO)?
What is the net margin of Krebs Biochemicals and Industries Limited (KREBSBIO)?
What is the EBIT return on assets of Krebs Biochemicals and Industries Limited (KREBSBIO)?
What is the operating margin of Krebs Biochemicals and Industries Limited (KREBSBIO)?
How fast is revenue growing at Krebs Biochemicals and Industries Limited (KREBSBIO)?
How much free cash flow does Krebs Biochemicals and Industries Limited (KREBSBIO) generate?
How much net debt does Krebs Biochemicals and Industries Limited (KREBSBIO) carry?
Watch Krebs Biochemicals and Industries Limited in the live analysis
One click puts Krebs Biochemicals and Industries Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.